SEARCH

SEARCH BY CITATION

References

  • 1
    Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 157080.
  • 2
    Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clin Liver Dis 2000; 4: 97113.
  • 3
    Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31: 70511.
  • 4
    Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994; 35: 2605.
  • 5
    Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994; 18: 919.
  • 6
    Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18: 105.
  • 7
    Sánchez-Pobre P, Castellano G, Colina F, et al. Antimitochon- drial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis? J Clin Gastroenterol 1996; 23: 1918.
  • 8
    Kloppel G, Kirchhof M, Berg PA. Natural course of primary biliary cirrhosis. I. A morphological, clinical and serological analysis of 103 cases. Liver 1982; 2: 14151.
  • 9
    Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000; 32: 12940.
  • 10
    Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000; 95: 11308.
    Direct Link:
  • 11
    Medina J, Jones EA, Garcia-Monzon C, Moreno-Otero R. Immunopathogenesis of cholestatic autoimmune liver diseases. Eur J Clin Invest 2001; 31: 6471.
  • 12
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 12318.
  • 13
    Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995; 40: 123242.
  • 14
    Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 10905.
  • 15
    Nakanuma Y, Harada K, Kaji K, et al. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 1997; 17: 2817.
  • 16
    Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995; 90: 2479.
  • 17
    Masuda J, Omagari K, Matsuo I, et al. Changes in titers of antimitochondrial and antinuclear antibodies during the course of primary biliary cirrhosis. J Gastroenterol Hepatol 2001; 16: 23943.
  • 18
    Neuberger J, Thomson R. PBC and AMA—what is the connection? Hepatology 1999; 29: 2716.
  • 19
    Nakajima M, Shimizu H, Miyazaki A, Watanabe S, Kitami N, Sato N. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis? J Gastroenterol 1999; 34: 60712.
  • 20
    Kim WR, Poterucha JJ, Jorgensen RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 226.
  • 21
    Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001; 34: 2438.
  • 22
    Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107: 183943.
  • 23
    Cho YJ, Han DS, Kim TY, et al. Negative conversion of antimitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis. J Korean Med Sci 1999; 14: 1026.
  • 24
    Solis Herruzo JA. Autoimmune cholangiopathy. Gastroenterol Hepatol 1996; 19: 2136.
  • 25
    Ludwig J. The pathology of primary biliary cirrhosis and autoimmune cholangitis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 60113.
  • 26
    Heathcote J. Autoimmune cholangitis. Gut 1997; 40: 4402.
  • 27
    Gordon SC, Quattrociocchi-Longe TM, Khan BA, et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995; 108: 18029.
  • 28
    Muratori P, Muratori L, Lenzi M, Bianchi FB. Antibodies to carbonic anhydrase in autoimmune cholangiopathy. Gastroenterology 1997; 112: 10534.
  • 29
    Akisawa N, Nishimori I, Miyaji E, et al. The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients. J Gastroenterol 1999; 34: 36671.
  • 30
    Invernizzi P, Battezzati PM, Crosignani A, et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998; 114: 44854.
  • 31
    Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999; 29: 166871.
  • 32
    Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 11969.
  • 33
    Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 5616.
  • 34
    Czaja AJ. Treatment of autoimmune hepatitis. In: ArroyoV, BoschJ, BruixJ, GinésP, NavasaM, RodésJ, eds. Therapy in Hepatology. Barcelona: Ars Médica, 2001: 99108.
  • 35
    Ishibashi H. Are primary biliary cirrhosis and autoimmune cholangitis reflective of the pendulum of a clock and therefore represent a ‘phase’ of the same disease? J Gastroenterol Hepatol 2001; 16: 1213.
  • 36
    Li CP, Hwang SJ, Chan CY, et al. Clinical evaluation of primary biliary cirrhosis in Chinese patients without serum anti- mitochondrial antibody. Chung Hua I Hsueh Tsa Chih (Taipei) 1997; 59: 33440.
  • 37
    Saló J, Caballería L, Bruguera M, Parés A, Rodés J. Autoimmune cholangitis or primary biliary cirrhosis without antimitochondrial antibodies? Gastroenterol Hepatol 1997; 20: 510.
  • 38
    Kinoshita H, Omagari K, Whittingham S, et al. Autoimmune cholangitis and primary biliary cirrhosis—an autoimmune enigma. Liver 1999; 19: 1228.
  • 39
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 88490.
  • 40
    Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 105360.
  • 41
    Omagari K, Ikuno N, Matsuo I, et al. Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis. Pathology 1996; 28: 2558.
  • 42
    Mohr L, Heintges T, Hensel F, Niederau C, Haussinger D. Treatment of autoimmune cholangitis. Dig Dis Sci 1998; 43: 21603.
  • 43
    Primo J, Miralles A, Ferrando J, et al. Atypical primary biliary cirrhosis or autoimmune cholangitis? Gastroenterol Hepatol 1999; 22: 5059.
  • 44
    Romero Gomez M, Wichmann I, Otero Fernandez MA, et al. Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis. Gastroenterol Hepatol 1999; 22: 113.
  • 45
    Devesa F, Ferrando MJ, Bustamante M, et al. Autoimmune cholangitis or autoimmune hepatitis with cholestatic component. Gastroenterol Hepatol 2001; 24: 1434.
  • 46
    Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976; 71: 4449.
  • 47
    Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10: 4209.
  • 48
    Brunner G, Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch Med Wochenschr 1987; 112: 14548.
  • 49
    Marinho R, Graca H, Ramalho F, Costa A, Batista A, De Moura MC. Autoimmune cholangitis: case report. Hepatogastroenterology 1999; 46: 194952.
  • 50
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 3605.
  • 51
    Sherlock S. Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity? Mayo Clin Proc 1998; 73: 18490.
  • 52
    Mitry E, Algayres JP, Bili H, et al. Autoimmune cholangitis successfully treated with corticotherapy. One case. Gastroenterol Clin Biol 1998; 22: 947.
  • 53
    Masumoto T, Ninomiya T, Michitaka K, et al. Three patients with autoimmune cholangiopathy treated with prednisolone. J Gastroenterol 1998; 33: 90913.
  • 54
    Ogata H, Tsuji H, Hashiguchi M, Azuma K, Shimono J, Fujishima M. Autoimmune cholangiopathy associated with rheumatoid arthritis. Hepatogastroenterology 2000; 47: 15334.
  • 55
    Castro F, Narvaez F, Vilaseca J. Autoinmune cholangitis with good response to corticoids. Gastroenterol Hepatol 2001; 24: 462.
  • 56
    Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001; 49: 58994.
  • 57
    Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125: 58898.
  • 58
    Mackay IR. Autoimmune disease overlaps and the liver: two for the price of one? J Gastroenterol Hepatol 2000; 15: 38.
  • 59
    Li CP, Tong MJ, Hwang SJ, et al. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J Gastroenterol Hepatol 2000; 15: 958.
  • 60
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296301.
  • 61
    Lohse AW, Zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29: 107884.
  • 62
    Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35: 40913.